(Q42679169)

4 November 2017

An open-label long-term phase III extension trial to evaluate the safety and efficacy of pregabalin in Japanese patients with fibromyalgia (English)

1 reference

4 November 2017

phase III clinical trial

0 references

fibromyalgia

0 references

author name string

Hiroyoshi Ohta

1

1 reference

4 November 2017

Hiroshi Oka

2

1 reference

4 November 2017

Chie Usui

3

1 reference

4 November 2017

Masayuki Ohkura

4

1 reference

4 November 2017

Makoto Suzuki

5

1 reference

4 November 2017

Kusuki Nishioka

6

1 reference

4 November 2017

1 December 2012

1 reference

4 November 2017

1 reference

4 November 2017

23

1 reference

4 November 2017

6

1 reference

4 November 2017

1108-1115

1 reference

Mechanisms of Disease: genetics of fibromyalgia

4 November 2017

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

The Japanese version of the 2010 American College of Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia and the Fibromyalgia Symptom Scale: reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

The health status burden of people with fibromyalgia: a review of studies that assessed health status with the SF-36 or the SF-12.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

The comparative burden of mild, moderate and severe fibromyalgia: results from a cross-sectional survey in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Impact of fibromyalgia severity on health economic costs: results from a European cross-sectional study

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Emerging concepts in the neurobiology of chronic pain: evidence of abnormal sensory processing in fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

A 14-week, randomized, double-blinded, placebo-controlled monotherapy trial of pregabalin in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

An international, randomized, double-blind, placebo-controlled, phase III trial of pregabalin monotherapy in treatment of patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Development of the Japanese version of the Fibromyalgia Impact Questionnaire (JFIQ): psychometric assessments of reliability and validity

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Fibromyalgia relapse evaluation and efficacy for durability of meaningful relief (FREEDOM): a 6-month, double-blind, placebo-controlled trial with pregabalin

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

Pregabalin treatment for peripheral neuropathic pain: a review of safety data from randomized controlled trials conducted in Japan and in the west

21 January 2018

1 reference

https://api.crossref.org/works/10.3109%2FS10165-012-0803-X

10.3109/S10165-012-0803-X

21 January 2018

Identifiers

DOI

1 reference

4 November 2017

1 reference